CAMBRIDGE, UK and CAMBRIDGE, USA, March 23, 2026: Abselion, a pioneering life sciences technology company focused on simplifying the quantification of biomolecules, today announced the appointment of Dale Gordon as Chairman of the Board. His appointment strengthens Abselion’s governance and board-level expertise, adding experienced commercial and bioprocess leadership as the company continues to develop its global commitments, building on its recently established U.S. subsidiary.
Abcelion is committed to building a well-managed organization that can support collaboration and reliable delivery as interest in the Amperia™ protein quantification system grows internationally. As Chair, Dale will help ensure sustainable growth and long-term value creation to meet the needs of academic, biotech, and pharmaceutical teams involved in biologics characterization, development, and manufacturing workflows.
Dale has more than 30 years of experience across the life sciences sector, with a background spanning bioprocessing, company formation, and board leadership. Most recently, he served as CEO of Mirus Bio, a leading provider of transfection technologies widely used in viral vector production, leading the business through a period of significant growth and strategic development. He also served as CEO of Gemini Bio and has held leadership roles at GE Life Sciences (now Cytiva) and Merck Millipore.
Having worked extensively with growth-stage life sciences companies, Dale brings valuable perspective on scaling technology from initial implementation to broader commercial deployment. His experience guiding these companies through growth and transition will help support clearer strategic oversight, strong governance, and effective decision-making as Abselion continues to evolve.
Dale will succeed Simon Douglas, who is retiring after more than four years as chairman of the board.
Dr Ruizhi Wang, CEO and Founder of Abselion, said:
“Dale is known for his expertise and strategic leadership in bioprocessing. His appointment strengthens our ability to make clear and confident decisions as we continue to build a business with long-term impact.”
Dale joins the company at a time when the company is moving from early momentum to a more execution-focused phase, with increasing commercial engagement and international activity. His experience guiding life science companies through this transition will be a valuable asset as we continue to expand globally.
I would also like to express my sincere gratitude to Simon for his insightful contributions and support during a critical period in the company’s early development. ”
Dale Gordon, Chairman of Abselion’s Board of Directors, said:
“Abselion has built a strong scientific foundation with a clear focus on addressing practical challenges in cell and gene therapy and biopharmaceutical development and production workflows. I see great opportunity in how the company is translating that work into real-world applications. I look forward to working with the board to support the company’s continued growth, strengthen its commercial direction, and help guide the next stage of its journey.”
For more information about Abselion’s team, please visit https://www.abselion.com/team/.
Abselion
Dr. Ann Sheeke
Phone: +44 7351 738 852
Email: (email protected)
codon communication
Dr. Michelle Ricketts
Phone: +44 7789 053885
Email: (email protected)
